A randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma
AA Brandes, M Gil‐Gil, F Saran, AF Carpentier… - The …, 2019 - academic.oup.com
Background We assessed the efficacy and safety of bevacizumab (BEV) through multiple
lines in patients with recurrent glioblastoma who had progressed after first‐line treatment …
lines in patients with recurrent glioblastoma who had progressed after first‐line treatment …
[HTML][HTML] A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent …
AA Brandes, M Gil‐Gil, F Saran, AF Carpentier… - The …, 2019 - ncbi.nlm.nih.gov
Background. We assessed the efficacy and safety of bevacizumab (BEV) through multiple
lines in patients with recurrent glioblastoma who had progressed after first-line treatment …
lines in patients with recurrent glioblastoma who had progressed after first-line treatment …
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent …
AA Brandes, M Gil-Gil, F Saran… - …, 2019 - research-repository.uwa.edu.au
Background: We assessed the efficacy and safety of bevacizumab (BEV) through multiple
lines in patients with recurrent glioblastoma who had progressed after first-line treatment …
lines in patients with recurrent glioblastoma who had progressed after first-line treatment …
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent …
AA Brandes, M Gil-Gil, F Saran, AF Carpentier… - …, 2018 - u-bourgogne.hal.science
BACKGROUND: We assessed the efficacy and safety of bevacizumab (BEV) through
multiple lines in patients with recurrent glioblastoma who had progressed after first-line …
multiple lines in patients with recurrent glioblastoma who had progressed after first-line …
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent …
AA Brandes, M Gil-Gil, F Saran, AF Carpentier… - Oncologist, 2018 - hal.science
BACKGROUND: We assessed the efficacy and safety of bevacizumab (BEV) through
multiple lines in patients with recurrent glioblastoma who had progressed after first-line …
multiple lines in patients with recurrent glioblastoma who had progressed after first-line …
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent …
AA Brandes, M Gil-Gil, F Saran… - The …, 2019 - pubmed.ncbi.nlm.nih.gov
Background We assessed the efficacy and safety of bevacizumab (BEV) through multiple
lines in patients with recurrent glioblastoma who had progressed after first-line treatment …
lines in patients with recurrent glioblastoma who had progressed after first-line treatment …
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent …
AA Brandes, M Gil-Gil, F Saran, AF Carpentier… - The Oncologist, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
We assessed the efficacy and safety of bevacizumab (BEV) through multiple lines in patients …
We assessed the efficacy and safety of bevacizumab (BEV) through multiple lines in patients …
[PDF][PDF] A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent …
AA Brandes, M Gil‐Gil, F Saran, AF Carpentier… - The …, 2019 - Wiley Online Library
Background We assessed the efficacy and safety of bevacizumab (BEV) through multiple
lines in patients with recurrent glioblastoma who had progressed after first‐line treatment …
lines in patients with recurrent glioblastoma who had progressed after first‐line treatment …
[PDF][PDF] A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent …
AA BRANDES, M GIL-GIL, F SARAN, AF CARPENTIER… - 2018 - academia.edu
Background. We assessed the efficacy and safety of bevacizumab (BEV) through multiple
lines in patients with recurrent glioblastoma who had progressed after first-line treatment …
lines in patients with recurrent glioblastoma who had progressed after first-line treatment …
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent …
AA Brandes, M Gil-Gil, F Saran, AF Carpentier… - The …, 2018 - europepmc.org
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous
Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. - Abstract …
Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. - Abstract …